Magnetic Stimulation Market Enters a New Competitive Phase, Testing Sustainable Technological Innovation Capabilities

Magnetic stimulation technology, as a non-invasive physical therapy modality with no side effects, demonstrates significant market potential in the fields of psychiatry and psychology, neurological rehabilitation, pediatric rehabilitation, postpartum rehabilitation, and pain management.

In recent years, the diversification of patient and clinical needs, the optimization of the policy environment, and the widespread adoption of technology have jointly driven the rapid development of the magnetic stimulation market, which has now entered a new phase of competition.

In recent years, the incidence of neuropsychiatric disorders has been steadily rising, encompassing conditions such as depression, anxiety-related insomnia, Alzheimer’s disease, Parkinson’s disease, and post-stroke sequelae. This trend underscores the urgent need for highly effective and safe therapeutic interventions.

In this context, magnetic stimulation technology has achieved significant results in the rehabilitation treatment of these diseases, leveraging its advantages of being non-invasive and free from side effects, and has rapidly become the preferred physical therapy modality for both patients and healthcare providers.

As the global population ages at an accelerating pace, the application of magnetic stimulation technology in the medical field is becoming increasingly widespread, demonstrating its strong versatility. Meanwhile, national-level initiatives are actively promoting the substitution of imported medical devices with domestically produced alternatives and vigorously supporting medical innovation, providing robust policy support and favorable opportunities for the vigorous development of the magnetic stimulation medical device industry.

It is worth noting that magnetic stimulation technology has been incorporated into the national healthcare reimbursement systems by governments in multiple countries and regions, including the United States, many European nations, and certain parts of China. This move has significantly reduced the financial burden on patients, accelerated the widespread adoption and application of the technology, and thereby driven rapid growth in market demand.

From transcranial magnetic stimulation to pelvic floor magnetic stimulation and peripheral magnetic stimulation, the application scope of magnetic stimulation technology continues to expand, with its technological maturity steadily improving. The widespread adoption and in-depth application of these technologies have provided strong momentum for the rapid growth of the magnetic stimulation market.

According to conservative estimates by market research firms, the current installed base of magnetic stimulation devices in China is approaching 15,000 units. Meanwhile, the global market for magnetic stimulation therapy devices is experiencing rapid growth, with a compound annual growth rate (CAGR) exceeding 10%. The market size is projected to reach billions of U.S. dollars by 2025.

The application scenarios of magnetic stimulation technology are becoming increasingly diverse, with its presence ubiquitous across healthcare settings ranging from tertiary hospitals to primary care facilities.

Currently, magnetic stimulation devices primarily include transcranial magnetic stimulators for central nervous system modulation, which are widely used in psychiatry and psychology, neurological rehabilitation, and pediatric rehabilitation; as well as pelvic floor magnetic stimulators mainly designed for peripheral stimulation, which are predominantly employed in pelvic floor rehabilitation.

Each manufacturer has cultivated its niche based on its technical expertise and market demands, creating a competitive landscape with distinct characteristics.

Wuhan Yiruide Medical Equipment New Technologies Co., Ltd. (hereinafter referred to as “Wuhan Yiruide”): As the inventor and leading enterprise of magnetic stimulation technology in China, Yiruide has established a comprehensive product portfolio covering diagnosis and rehabilitation of brain disorders, non-invasive brain monitoring, and neuromodulation since its establishment in 2007. Its products, including the 100Hz repetitive transcranial magnetic stimulator, deep transcranial magnetic stimulator, magnetic seizure therapy device, magnetic stimulation robot, and near-infrared brain function imaging system, which were pioneered in China, are all at the forefront of the industry. In clinical and research fields such as psychiatry and psychology, neurological rehabilitation, and pediatric rehabilitation, Yiruide serves over 5,000 users, with its transcranial magnetic stimulation products maintaining long-term leadership in both user base and market share.

Nanjing Vishee Medical Technology Co., Ltd. (hereinafter referred to as “Nanjing Vishee”): As a company listed on the STAR Market, Nanjing Vishee specializes in the research and development, manufacturing, and sales of rehabilitation medical devices. Its products cover multiple fields, including pelvic floor and postpartum rehabilitation, psychiatric and psychological rehabilitation, neurological rehabilitation, pediatric rehabilitation, and medical aesthetics. The product portfolio includes magnetic stimulation, electrical stimulation, electrophysiology, rehabilitation robotics, radiofrequency, and laser-based devices, with a user focus primarily on rehabilitation, women’s health, and pediatrics.

Wuhan Aosaifu Medical Technology Co., Ltd. (hereinafter referred to as “Wuhan Aosaifu”): Since its establishment in 2012, Wuhan Aosaifu has distinguished itself in the market with products such as dual-pulse source transcranial magnetic stimulation (TMS) devices and pelvic floor magnetic stimulators. These versatile, multi-functional devices have been widely favored by clients in the fields of mental health, neurological rehabilitation, pelvic floor rehabilitation, and postpartum recovery, earning a notable reputation particularly among primary and secondary hospitals and medical institutions.

Shenzhen Yingzhi Technology Co., Ltd. (hereinafter referred to as “Shenzhen Yingzhi”): As a wholly-owned subsidiary of Shenzhen Hanxiang, Shenzhen Yingzhi specializes in providing products and services for the precise diagnosis and treatment of brain and neurological disorders. Its main products include electroencephalographs, electromyography and evoked potential detection systems, brain function monitoring systems, transcranial magnetic stimulators, and near-infrared brain function imaging systems, with research users accounting for a significant proportion.

In addition to the four companies mentioned above, brands such as “Jiangxi Brain Modulation,” “Sichuan Junjian Wanfeng,” “Henan Youde,” and “Henan Max” also frequently appear in the market, collectively forming a diversified competitive landscape in the field of magnetic stimulation.

Notably, according to equity penetration data from Tianyancha and publicly available information, Wuhan IRAD Medical Equipment New Technology Co., Ltd. has established wholly-owned control over Wuhan Aosaifu Medical Technology Co., Ltd., Wuhan Zilian Hongkang Technology Co., Ltd., and Wuhan Yimai Medical Technology Co., Ltd. These four enterprises have integrated to form the IRAD Group, with its business focus fully shifted toward the brain science sector, primarily centered on brain monitoring and neuromodulation technologies.

In this case, the Yiruide Group holds the majority share of China's magnetic stimulation market.

In the field of magnetic stimulation R&D and manufacturing, manufacturers should prioritize sustainable technological innovation and the dual enhancement of quality and technology over price competition, thereby earning user trust.

Reviewing the development trajectory of magnetic stimulation technology, Chinese magnetic stimulators have surpassed foreign “air-cooling” technologies with their independently developed inert liquid internal circulation cooling system—“liquid-cooling” technology—thereby establishing a technical foundation that rivals or even exceeds international leading standards.

Subsequently, the dual-coil magnetic stimulator, tailored to Chinese medical scenarios, has garnered acclaim from the domestic clinical medical community for its high treatment efficiency.

Nowadays, manufacturers are increasingly positioning “deeper, more extensive, stronger, and more precise” pulsed magnetic field output and “intelligence” as the key factors for future competition, while ramping up investments in emerging technological areas such as deep brain magnetic stimulation, multi-coil configurations, magnetic seizure therapy, and intelligently navigated magnetic stimulation.

The continuous iteration and upgrading of cutting-edge technologies pose a severe test to enterprises' sustainable technological innovation capabilities.

According to publicly available information:

Wuhan Yiruide obtained the first NMPA (National Medical Products Administration of China) registration certificate for a magnetic stimulator in China in 2009. It secured approval for a dual-pulse source with dual-coil combination in 2019, received certification for deep coils in 2021, and obtained the NMPA registration certificate for intelligent navigation magnetic stimulation in 2022. In the same year, its super magnetic stimulator capable of delivering magnetic seizure therapy was officially launched on the market.

Vishee Medical obtained the NMPA registration certificate for its dual-pulse source combination system in 2022; its magnetic stimulation product for circumference reduction and body contouring received NMPA and U.S. FDA clearance in 2023; and it secured the NMPA registration certificate for navigated magnetic stimulation in 2024.

Wuhan Aosaifu was the first to obtain certification for its dual-pulse source, dual-coil combination in 2014, and received registration approval for its dual-coil pelvic floor magnetic stimulator in 2022.

Shenzhen Yingzhi’s deep coil is an agency product of a foreign company. It obtained EU CE certification in 2016, received NMPA registration for navigated magnetic stimulation in 2021, obtained NMPA registration for the dual-coil combination in 2022, and its M series products received US FDA clearance in 2023.

It is reported that on October 26, 2024, Wuhan Yiruide released a multi-target loop magnetic stimulator (research version) with four pulse sources and four coils. This product is technologically leading both in China and globally, and has currently entered the clinical validation phase.

Looking ahead, as patient and clinical needs become increasingly diverse and the policy environment continues to improve, Chinese manufacturers of magnetic stimulation technology will continue to leverage their respective technical advantages and market positioning to drive innovation and application in this field. With ongoing technological advancements and continued market segmentation, the magnetic stimulation market is poised for broader growth prospects, making greater contributions to healthcare.